Should I subscribe Krsnaa diagnostics IPO?

“A strong balance sheet and healthy operating cash flows should enable the company to pursue growth opportunities and fund its strategic initiatives. Hence, we recommend a “subscribe” rating on the issue,” the brokerage said.

Is Windlas Biotech IPO good?

The initial public offer of Windlas Biotech received bids for 13.78 crore shares as against 61.36 lakh shares on offer, according to stock exchange data. The issue was subscribed 22.47 times. The qualified institutional buyers (QIBs) category was subscribed 24.40 times.

Is exxaro oversubscribed?

The Exxaro IPO was oversubscribed by 4.67 times, followed by Windlas Biotech at 3.18 times, Devyani International at 2.69 times and Krsnaa Diagnostics at 1.98 times, exchange data showed.

Are exxaro tiles good?

“Exxaro Tiles has a better revenue growth track record compared with its peers (over FY18-21). We believe the valuation is reasonable. We recommend a ‘subscribe’ rating on the issue,” it said. For FY21, the company reported a 6 per cent rise in sales at Rs 255 crore.

Is exxaro tiles good for long term?

Exxaro Tiles is engaged in the manufacturing and marketing of different types of vitrified tiles used for flooring solutions. At around 12:30 PM, Exxaro Tiles was trading at Rs131….ATTENTION INVESTORS.

Can I invest in exxaro tiles?

The minimum investment by retail investors is Rs 15,000 per lot and the maximum is Rs 1.95 lakh for 13 lots. Up to 25 percent of the offer is reserved for qualified institutional buyers, 40 percent for retail investors and 35 percent for non-institutional investors. Exxaro Tiles makes and sells vitrified floor tiles.